Roche’s Evrysdi Approved For SMA, Priced Below Competitors

Oral drug will rival Biogen, Novartis therapies

 
• By Mandy Jackson

Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma. 

FDA Approved text, inscription, phrase is written in a notebook that lies on a wooden table and a pen. Business concept.
Evrysdi is the first oral, but third disease-modifying therapy for SMA • Source: Shutterstock

More from New Products

More from Scrip